EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization

Diane M Wilcock, Eric Goold iD, Lauren M Zuromski, Christian Davidson, Qinwen Mao, Deepika Sirohi

Journal of Neuropathology & Experimental Neurology · 2024

DOI: 10.1093/jnen/nlae028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuropathology & Experimental Neurology, 2024. Verfasst von Diane M Wilcock und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Experimental Pathology, ARUP Laboratories, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioblastoma, Glioma, Gene Amplification. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

EGFR amplification in gliomas is commonly defined by an EGFR/CEP7 ratio of ≥2. In testing performed at a major reference laboratory, a small subset of patients had ≥5 copies of both EGFR and CEP7 yet were not amplified by the EGFR/CEP7 ratio and were designated high polysomy cases. To determine whether these tumors are more closely related to traditionally defined EGFR-amplified or nonamplified gliomas, a retrospective search identified 22 out of 1143 (1.9%) gliomas with an average of ≥5 copies/cell of EGFR and CEP7 with an EGFR/CEP7 ratio of <2 displaying high polysomy. Of these cases, 4 had insufficient clinicopathologic data to include in additional analysis, 15 were glioblastomas, 2 were IDH-mutant astrocytomas, and 1 was a high-grade glial neoplasm, NOS. Next-generation sequencing available on 3 cases demonstrated one with a TERT promoter mutation, TP53 mutations in all cases, and no EGFR mutations or amplifications, which most closely matched the nonamplified cases. The median overall survival times were 42.86, 66.07, and 41.14 weeks for amplified, highly polysomic, and nonamplified, respectively, and were not significantly different (p = 0.3410). High chromosome 7 polysomic gliomas are rare but our data suggest that they may be biologically similar to nonamplified gliomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsGlioblastomaGliomaGene AmplificationHumansChromosome AberrationsErbB ReceptorsIn Situ Hybridization, FluorescenceIsocitrate DehydrogenaseMutationRetrospective StudiesChromosomes, Human, Pair 7

Stichwörter der Autor:innen

AstrocytomaChromosome 7 polysomyEGFR FISHEGFR amplificationEGFR/CEP7 coamplificationGlioblastomaIDH-wildtype glioma

Substanzen

EGFR protein, humanErbB ReceptorsIsocitrate Dehydrogenase

Autor:innen und Institutionen

  • Institute for Experimental Pathology, ARUP Laboratories, Salt Lake City, Utah, USA.
  • Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, Utah, USA.

ORCID-Profile: Eric Goold

Zitieren

APA

Wilcock, D. M., Goold, E., Zuromski, L. M., Davidson, C., Mao, Q., & Sirohi, D. (2024). EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlae028

Vancouver

Wilcock DM, Goold E, Zuromski LM, Davidson C, Mao Q, Sirohi D. EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization. Journal of Neuropathology & Experimental Neurology. 2024. doi:10.1093/jnen/nlae028

BibTeX
@article{Wilcock2024,
  author = {Wilcock, Diane M and Goold, Eric and Zuromski, Lauren M and Davidson, Christian and Mao, Qinwen and Sirohi, Deepika},
  title = {EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization},
  journal = {Journal of Neuropathology & Experimental Neurology},
  year = {2024},
  doi = {10.1093/jnen/nlae028}
}
Kostenlos starten →